Encyclopedia of Metalloproteins

2013 Edition
| Editors: Robert H. Kretsinger, Vladimir N. Uversky, Eugene A. Permyakov

Proteomic Basis of Cisplatin Resistance

Reference work entry
DOI: https://doi.org/10.1007/978-1-4614-1533-6_555



Cisplatin along with other platinum-based drugs including oxaliplatin, carboplatin are some of the most widely used chemotherapeutic agents. Unfortunately, drug resistance remains a major problem for the successful chemotherapeutic treatment of cancer. Current evidence suggests that resistance toward platinum chemotherapeutics is a multifactorial problem due to changes in the expression levels and activities of a wide number of proteins.

Cisplatin Resistance and Changes to the Proteome

The primary goal of cancer chemotherapy is to disrupt tumor cell growth by interfering with cell division (mitosis) or activating programmed cell death pathways (apoptosis). The powerful anticancer properties of cisplatin (( SP-4-2)-diamminedichloridoplatinum, cis-PtCl 2(NH 3)2) were first discovered by accident in a series of studies carried out in the 1960s and 1970s. The United States Food and Drug Administration...
This is a preview of subscription content, log in to check access



This laboratory is grateful for support from the National Institutes of Health through grant numbers: 5R01RR023334, 1R01GM097112, 5R01GM086688, 7S10RR025107, and 1R01HL110879.


  1. Chavez JD, Hoopmann MR et al (2011) Quantitative proteomic and interaction network analysis of cisplatin resistance in HeLa cells. PLoS One 6(5):e19892PubMedGoogle Scholar
  2. Jensen R, Glazer PM (2004) Cell-interdependent cisplatin killing by Ku/DNA-dependent protein kinase signaling transduced through gap junctions. Proc Natl Acad Sci USA 101(16):6134–6139PubMedGoogle Scholar
  3. Kartalou M, Essigmann JM (2001) Mechanisms of resistance to cisplatin. Mutat Res 478(1–2):23–43PubMedGoogle Scholar
  4. Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7(8):573–584PubMedGoogle Scholar
  5. Lindstrom MS (2009) Emerging functions of ribosomal proteins in gene-specific transcription and translation. Biochem Biophys Res Commun 379(2):167–170PubMedGoogle Scholar
  6. Mussunoor S, Murray GI (2008) The role of annexins in tumour development and progression. J Pathol 216(2):131–140PubMedGoogle Scholar
  7. Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22(47):7265–7279PubMedGoogle Scholar
  8. Trachootham D, Alexandre J et al (2009) Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8(7):579–591PubMedGoogle Scholar
  9. Zhang JT, Liu Y (2007) Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment. Cancer Treat Rev 33(8):741–756PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Genome SciencesUniversity of WashingtonSeattleUSA